Heuron collaborates with Singaporean hospital on healthcare AI research

Heuron, a medical AI company specializing in neurological diseases, said Thursday that it installed two of its Alzheimer's predictive diagnostic solutions at the National University Hospital (NUH) in Singapore in April.

The AI solutions are Heuron AD, an AI solution for quantitative analysis of brain atrophy, and Heuron Brain PET, an AI solution for quantitative analysis of PET (positron emission tomography).

In March, Heuron began a research collaboration with the National University Hospital of Singapore to conduct a retrospective study on AI-assisted staging of Alzheimer's disease.

The study uses imaging data from more than 700 brain MRI scans and 230 brain PET scans. The data will be continuously imaged at one, two, four, and five years after the onset of the disease in normal, mildly cognitively impaired, and Alzheimer's patients to validate how accurately Heuron's solution measures normal, mildly cognitively impaired, and Alzheimer's, demonstrating its potential for clinical use for early diagnosis and treatment of Alzheimer's.

Professor Christopher Chen, director of the Memory Aging & Cognition Center at the National University of Singapore and a world-renowned authority on neurodegenerative diseases, will lead the study as principal investigator. Professor Pei Ing Ngam at the National University of Singapore will also participate as the main investigator. The results will be formally published in a journal.

"We are pleased to be able to utilize the high-quality data accumulated over the years by the National Hospital of Singapore through this research collaboration," Heuron CEO Shin Dong-hoon said. "We hope this study will provide a great opportunity to closely validate the validity of Heuron AD and Heuron Brain PET and open up the possibility of clinical applications."